Biggest Movers in Healthcare: INSYS Therapeutics, Inc. (INSY), The Medicines Company (MDCO)

Andrew Cummings
February 25, 2017

Insys Therapeutics Inc (NASDAQ:INSY) will announce its earnings results before the market opens on Tuesday, February 21st. RBC Capital Markets set a $16.00 price target on shares of Insys Therapeutics and gave the company a "buy" rating in a research report on Sunday, January 8th. Given that its average daily volume over the 30 days has been 1.03 million shares a day, this signifies a pretty significant change over the norm. The 52-week high of the share price is $21.22 and the 52-week low is $8.7.

The stock was able to keep return on assets at 7.19% in the trailing twelve month while Reuters data showed that industry's average stands at -0.77% and sector's optimum level is -8.43%. The short ratio in the company's stock is documented at 14.46 and the short float is around of 66.71%.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Price to Earnings (P/E) ratio is 40.38. The company reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. The company shows Gross Margin and Operating Margin of 92 percent and 13.1 percent respectively. The stock price recently experienced a 5-day gain of 39.83% with 0.66 average true range (ATR). Based on the filings, last years Annual Earnings was, $1.21.

Insys Therapeutics, a commercial-stage specialty pharmaceutical company. (NASDAQ:INSY) in a note sent to investors on 12-Nov-14. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics, Inc. with's FREE daily email newsletter. According to the corporate earnings calendar, Insys Therapeutics, Inc. will release next earnings on Feb 28, 2017 with an estimated EPS consensus of $-0.05.

Insys Therapeutics, Inc. has received $-0.05 as the consensus Earnings Estimate for the Quarter ending on Dec 2016, According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. (NASDAQ:INSY) beats earnings by 58%, The Stock Missed Earnings 3 times and has met earnings 1 times.

Insys Therapeutics, Inc. had its "perform" rating reiterated by analysts at Oppenheimer.

Price Target is an important factor while doing analysis of a stock. The Stock declined on the very next day of earnings and maintained its stock price at $10.02 by showing a % change of -2.81 percent from its previous closing price. On the 7th day After Earnings Report, the stock hit its share price as $13.56 by showing 31.52% increase from the Stock price Before Earnings were reported.

The Stock now has Analyst' mean Recommendation of 1.8 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell. Before Earnings Announcement on 08/03/2016, the firm had its stock price of $15.2.

The Medicines Company (MDCO) opened the session with a $52.14 price tag, later ranging from $51.49 to $52.58, the range at which the stock has traded at throughout the day. Insys Therapeutics, based in Phoenix, Arizona. (NASDAQ:INSY) surged to 27.5% from $15.2 to $19.38.

05/15/2015 - Insys Therapeutics, Inc. was upgraded to "strong-buy" by analysts at Zacks. The difference between the actual and expected EPS is $0.05 a share with a surprise factor of 250%. Thus showing a Surprise of 57.1 percent. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.07 while the top line estimate is $-0.03, a key information to consider for Day Trading and investing in stocks.

Other reports by iNewsToday